Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of financial medication assistance on medication adherence: a systematic review.
Hung A, Blalock DV, Miller J, McDermott J, Wessler H, Oakes MM, Reed SD, Bosworth HB, Zullig LL. Hung A, et al. J Manag Care Spec Pharm. 2021 Jul;27(7):924-935. doi: 10.18553/jmcp.2021.27.7.924. J Manag Care Spec Pharm. 2021. PMID: 34185554 Free PMC article.
Impacts on patient out-of-pocket costs were mixed; two studies reported that out-of-pocket costs were higher for users of a coupon or a voucher versus nonusers, one study reported the opposite, and one study reported null effects. ...PhRMA had no role in study desig …
Impacts on patient out-of-pocket costs were mixed; two studies reported that out-of-pocket costs were higher for users of a coupon or …
Association of Transcatheter Aortic Valve Replacement Reimbursement, New Technology Add-on Payment, and Procedure Volumes With Embolic Protection Device Use.
Lowenstern A, Hung A, Manandhar P, Wegermann ZK, Kapadia SR, Lindman BR, Goel K, Levack M, Barker CM, Reed SD, Cohen DJ, Vemulapalli S. Lowenstern A, et al. Among authors: hung a. JAMA Cardiol. 2022 Sep 1;7(9):945-952. doi: 10.1001/jamacardio.2022.2608. JAMA Cardiol. 2022. PMID: 35976635 Free PMC article.
Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide.
Hung A, Sinclair M, Hemmersbach-Miller M, Edmonston D, Wyatt C. Hung A, et al. J Manag Care Spec Pharm. 2020 Dec;26(12):1582-1588. doi: 10.18553/jmcp.2020.26.12.1582. J Manag Care Spec Pharm. 2020. PMID: 33251997 Free PMC article.
BACKGROUND: Tenofovir alafenamide (TAF) is a new formulation of tenofovir disoproxil fumarate (TDF) that was approved in 2015. ...The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Hea …
BACKGROUND: Tenofovir alafenamide (TAF) is a new formulation of tenofovir disoproxil fumarate (TDF) that was approved in 2015. ...The …
903 results